Table 4.

Multivariate analysis of risk factors for hepatotoxicity in APL patients undergoing ATO treatment

Variables	Unfavorable category	Overall patients			Unfavorable category	Early hepatotoxicity
		OR	95% CI	P		OR	95% CI	P
Age	≥ 50	2.077	0.377–11.429	0.401	≤ 50	2.058	0.744–5.693	0.164
Fibrinogen level, g/L	≥ 1	3.665	0.685–19.598	0.129	< 1	3.496	1.127–10.846	0.030*
Hemoglobin level, g/L	≥ 80	8.653	1.339–55.921	0.023*	≥ 80	1.756	0.662–4.659	0.258
Sex	female	2.472	0.434–14.065	0.308	male	2.202	0.820–5.841	0.113
Platelet count, × 109/L	< 30	4.356	0.786–24.141	0.092	< 30	2.373	0.886–6.354	0.086
Prophylactic hepatoprotective agents	No	14.531	2.349–89.879	0.004**	No	36.455	7.409–179.364	0.000**
Single ATO	No	20.108	1.357–297.893	0.029*	No	4.288	1.363–13.492	0.013*

OR, odds ratio; CI, confidence interval; Bold values and ^* are statistically significant (P < 0.05); bold values and ^** are statistically significant (P < 0.01); ATO, arsenic trioxide